Rajat Bose of rajatkbose.com recommends buying Novartis, Cipla, Bajaj Auto and Rain Industries.
All the medicines were tested in melanoma patients who had undergone surgery to cut out tumours and had a genetic mutation called BRAF, making them likely to respond to the targeted cancer pills. Patients with BRAF mutations constitute around half of the melanoma population.
Bringing you the latest news and updates.
Narasimhan will replace Joseph Jimenez, the incumbent CEO, who has informed the Board of Directors of his desire to step down in 2018, after eight years in position, the Basel-headquartered company said in a statement on Monday.
Jimenez is stepping down following a decade at Novartis after having successfully secured U.S. approval for a new gene therapy for leukemia last week but before Novartis returned to sales growth, which the company has forecast will resume in 2018.
The government's push for prescribing drugs by generic names could pose a further challenge.
Ilaris costs about USD 200,000 for a single year's treatment. Novartis makes around USD 250 million annually on the drug. But the new indication, if approved by the regulator, would expand the sales manifold,
Glenmark Pharmaceuticals, on Tuesday, said the US drug regulator cleared the company's investigational new drug (IND) application to initiate a first-in-human study of GBR 310, a proposed biosimilar, which will assess its pharmacokinetics in comparison to Novartis anti-asthma biologic XOLAIR or omalizumab in healthy adult volunteers between 18-65 years of age.
As global drug makers are exiting low priority brands, their Indian counterparts are lapping up the opportunity buying established products at perhaps low valuations.
Intas said it is undertaking a detailed analysis on reports of inflammation and has advised doctors to avoid using the product, meant to treat an age-related eye condition, from this specific batch.
Tobramycin inhalation had US sales of USD 133.6 million as on December 2016 according to IMS data.
The company has received final approval from the US Food and Drug Administration (USFDA) for its Tobramycin Inhalation Solution, the Mumbai-based company said in a statement.
Global drug major Novartis has invested, expanded its research & development (R&D) capabilities in India. The global leader in biosimilars through its subsidiary Sandoz is assessing Indian market dynamics to launch its portfolio.
The pan-European Stoxx 600 was 0.65 percent higher with all sectors trading positive.
"When we build a new manufacturing site we think about the tax rate, we think about the economy of the country, we think about jobs, so a booming US economy would make the US more attractive for investment," Joe Jimenez said on Wednesday.
Twenty-two companies, including Pfizer, Merck, Novartis, Roche, Sanofi and GlaxoSmithKline, will contribute funds and expertise to the project, which is backed by the World Bank.
Bengaluru-based biopharmaceutical firm Biocon on Wednesday said US drug regulator has accepted its partners Mylan‘s biologics license application (BLA) for the proposed biosimilar of breast cancer drug Trastuzumab through the 351(k) pathway.
The therapies called AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx have the potential to lower lipoproteins Lp(a) and ApoCIII by up to 90 percent, it said. Novartis has also entered into a stock purchase agreement with Ionis, it added without elaborating.
Selexys specialises in sickle cell disease, an inherited form of anaemia that is most common among people of African descent.
Wockhardt, Sun Pharma, Tara, Novartis and other pharma company Perrigo are also in focus on account of reports from the US that there are lawsuits filed by Unions representing the New York Police Department on price collusion of two dermatology products.
Several firms are reporting earnings Tuesday, including Novartis, Norsk Hydro, Randstand and Swedbank.
"These 14 prescription brands acquired by the company earlier this year will be transferred from Novartis Pharma K.K. to Sun Pharma's subsidiary in Japan beginning October 2016," Sun Pharma said in a statement today.
Andrew Aristidou, CFO and ED Finance, GSK Pharma, speaks about the company‘s new launches and why GSK Pharma is in no rush to delist in India.
Although the world's biggest prescription drugmaker's first-quarter core net income fell 13 percent to USD 2.79 billion, it beat the USD 2.76 billion average of estimates from analysts polled by Reuters and lifted the company's shares.
According to the agreements signed by the parties, a wholly-owned subsidiary of Sun Pharma will acquire the portfolio consisting of 14 established prescription brands from Novartis for a cash consideration of USD 293 million, Sun Pharma said in a statement.